Literature DB >> 4940475

Repeated assessment of results in clinical trials of cancer treatment.

J L Haybittle.   

Abstract

Entities:  

Mesh：

Year:  1971        PMID： 4940475     DOI： 10.1259/0007-1285-44-526-793

Source DB:  PubMed          Journal:  Br J Radiol        ISSN： 0007-1285            Impact factor:   3.039


× No keyword cloud information.
  111 in total

1.  A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis.

Authors:  Michael C Sneller; Zonghui Hu; Carol A Langford
Journal:  Arthritis Rheum       Date:  2012-03

2.  The evolution of ways of deciding when clinical trials should stop recruiting. Interview by Iain Chalmers.

Authors:  Peter Armitage
Journal:  J R Soc Med       Date:  2014-01       Impact factor: 5.344

3.  Vitamin D Supplementation and Prevention of Type 2 Diabetes.

Authors:  Anastassios G Pittas; Bess Dawson-Hughes; Patricia Sheehan; James H Ware; William C Knowler; Vanita R Aroda; Irwin Brodsky; Lisa Ceglia; Chhavi Chadha; Ranee Chatterjee; Cyrus Desouza; Rowena Dolor; John Foreyt; Paul Fuss; Adline Ghazi; Daniel S Hsia; Karen C Johnson; Sangeeta R Kashyap; Sun Kim; Erin S LeBlanc; Michael R Lewis; Emilia Liao; Lisa M Neff; Jason Nelson; Patrick O'Neil; Jean Park; Anne Peters; Lawrence S Phillips; Richard Pratley; Philip Raskin; Neda Rasouli; David Robbins; Clifford Rosen; Ellen M Vickery; Myrlene Staten
Journal:  N Engl J Med       Date:  2019-06-07       Impact factor: 91.245

4.  Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors.

Authors:  Tai-Tsang Chen
Journal:  J Natl Cancer Inst       Date:  2015-06-25       Impact factor: 13.506

Review 5.  Two-stage designs in bioequivalence trials.

Authors:  Helmut Schütz
Journal:  Eur J Clin Pharmacol       Date:  2015-01-22       Impact factor: 2.953

6.  Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

Authors:  Robert J Motzer; Naomi B Haas; Frede Donskov; Marine Gross-Goupil; Sergei Varlamov; Evgeny Kopyltsov; Jae Lyun Lee; Bohuslav Melichar; Brian I Rini; Toni K Choueiri; Milada Zemanova; Lori A Wood; M Neil Reaume; Arnulf Stenzl; Simon Chowdhury; Ho Yeong Lim; Ray McDermott; Agnieszka Michael; Weichao Bao; Marlene J Carrasco-Alfonso; Paola Aimone; Maurizio Voi; Christian Doehn; Paul Russo; Cora N Sternberg
Journal:  J Clin Oncol       Date:  2017-09-13       Impact factor: 44.544

7.  The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.

Authors:  Haleema Shakur; Diana Elbourne; Metin Gülmezoglu; Zarko Alfirevic; Carine Ronsmans; Elizabeth Allen; Ian Roberts
Journal:  Trials       Date:  2010-04-16       Impact factor: 2.279

8.  Control of hyperglycaemia in paediatric intensive care (CHiP): study protocol.

Authors:  Duncan Macrae; John Pappachan; Richard Grieve; Roger Parslow; Simon Nadel; Margrid Schindler; Paul Baines; Peter-Marc Fortune; Zdenek Slavik; Allan Goldman; Ann Truesdale; Helen Betts; Elizabeth Allen; Claire Snowdon; Deborah Percy; Michael Broadhead; Tara Quick; Mark Peters; Kevin Morris; Robert Tasker; Diana Elbourne
Journal:  BMC Pediatr       Date:  2010-02-05       Impact factor: 2.125

9.  Microbicides Development Programme: design of a phase III trial to measure the efficacy of the vaginal microbicide PRO 2000/5 for HIV prevention.

Authors:  Andrew Nunn; Sheena McCormack; Angela M Crook; Robert Pool; Clare Rutterford; Richard Hayes
Journal:  Trials       Date:  2009-10-27       Impact factor: 2.279

10.  The EPICS Trial: Enabling Parents to Increase Child Survival through the introduction of community-based health interventions in rural Guinea Bissau.

Authors:  Vera Mann; Ila Fazzio; Rebecca King; Polly Walker; Albino dos Santos; Jose Carlos de Sa; Chitra Jayanti; Chris Frost; Diana Elbourne; Peter Boone
Journal:  BMC Public Health       Date:  2009-08-03       Impact factor: 3.295
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.